What are the short-term safety data for PCSK9 inhibitors?
Short-term (<3 years) safety data for PCSK9 inhibitors suggest no increased risk for new-onset DM, no effect on neurocognitive function, and no difference in serious adverse events. The only significant treatment-emergent adverse effect was injection site reactions, which were statistically higher for evolocumab and alirocumab versus control.